Stoke Therapeutics (NASDAQ:STOK) Posts Earnings Results

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Thursday. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15), FiscalAI reports. The company had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.21 million. Stoke Therapeutics had a negative return on equity of 66.76% and a negative net margin of 862.07%.

Here are the key takeaways from Stoke Therapeutics’ conference call:

• EMPEROR Phase III remains on track: Approximately 110 of 162 patients have reached the week 28 primary endpoint visit, about 20 have completed the 52-week treatment period, and no patients have discontinued treatment. Stoke continues to expect topline data in Q3 2027.
• The FDA agreed that Stoke may use a multicomponent Vineland-3 assessment covering four cognitive and behavioral subdomains for the planned U.S. NDA. Management believes this approach better reflects Dravet syndrome’s variability and improves statistical power; the company does not currently anticipate an advisory committee meeting.
• Stoke is advancing its potential commercial launch of zorevunersen, estimating approximately 6,000 immediately addressable U.S. pediatric patients and increasing awareness among treatment centers, payers, and neurologists. The company is preparing patient services, market access, and treatment-site infrastructure for a potential launch in early 2028.
• The STK-002 program for autosomal dominant optic atrophy is progressing, with dosing underway in the third OSPREY cohort and a fourth cohort expected to begin in early 2027. Initial safety and efficacy data from higher-dose cohorts are anticipated in the first half of 2027.
• Stoke ended the quarter with $358.8 million in cash, cash equivalents, and marketable securities, while reporting a quarterly net loss of $73.6 million. Including expected Biogen reimbursements and a potential development milestone, management expects its cash position to fund operations into early 2028.

Stoke Therapeutics Trading Down 0.2%

Shares of Stoke Therapeutics stock traded down $0.06 on Friday, reaching $26.29. 1,856,809 shares of the company were exchanged, compared to its average volume of 1,198,577. The stock has a fifty day moving average price of $27.43 and a 200-day moving average price of $30.89. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -6.97 and a beta of 1.26. Stoke Therapeutics has a fifty-two week low of $20.32 and a fifty-two week high of $40.22.

Analyst Upgrades and Downgrades

STOK has been the topic of several research reports. Canaccord Genuity Group dropped their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They issued an “overweight” rating and a $40.00 target price on the stock. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 12,567 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the sale, the director owned 124,557 shares in the company, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the sale, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. The trade was a 26.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 34,594 shares of company stock worth $1,069,305 in the last quarter. 9.60% of the stock is owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.